Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis.

Next Previous
Trial Profile

A Phase 1/2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MIS 416 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Sponsors Amplia Therapeutics Limited; Innate Immunotherapeutics

Most Recent Events

  • 28 Apr 2017 Results (n=102) assessing effect of mutations in the gene NFKBIA on patients response to MIS416 using patient data from NCT02228213 and NCT01191996 trials, presented at the 69th Annual Meeting of the American Academy of Neurology
  • 28 Apr 2017 Results of profiling the kynurenine pathway and effect of MIS416 on Kynurenine pathway, presented at the 69th Annual Meeting of the American Academy of Neurology
  • 28 Apr 2017 Results (n=11) assessing neurological status of SPMS patients, presented at the 69th Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top